Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 9043 results

  1. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.

    Technology appraisal guidance
    In consultation

  2. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628

    In development Reference number: GID-TA11826 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    In development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. COLOFIT model to guide colorectal cancer pathway referral in primary care: early use assessment

    In development Reference number: GID-HTG10862 Expected publication date: TBC

    HealthTech guidance
    In development

  5. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]

    Awaiting development Reference number: GID-TA11969 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Spartan RX point-of-care CYP2C19 test

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development Reference number: GID-TA11538 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Vacuum Assisted Excision for the removal of breast lesions of uncertain malignant potential

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Omental lymph node transfer for lymphoedema of the limbs

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  14. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    In development Reference number: GID-TA11025 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  15. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development